Internal Medicine, Endocrinology, Diabetes, & Metabolism · El Paso, TX
NPI
1083617328
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1516 Lomaland Dr.
El Paso, TX, 79935
Phone (915) 593-2600
Groups this clinician bills Medicare through
Medicare paid, 2024
$76K
952 services
Medicare patients, 2024
278
Average age 73
Drug cost, 2024
$6.8M
15,066 prescriptions
Company payments, 2025
$5,536
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Benito A Marranzini was code 99214 (office e&m - established), 602 times for 250 patients. In total Benito A Marranzini billed 952 services in 12 codes, and Medicare paid $76K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-05-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 602 | 250 | $75.32 | $45K |
| 99215 Office E&M - Established | Office | 188 | 129 | $116.56 | $22K |
| 95251 Test - Miscellaneous | Office | 58 | 29 | $23.94 | $1,389 |
| 99205 Office E&M - New | Office | 39 | 39 | $129.49 | $5,050 |
| 83036 Blood Count | Office | 23 | 18 | $9.52 | $219 |
| 99213 Office E&M - Established | Office | 21 | 17 | $47.45 | $997 |
By year: 2022 $92K for 1,048 services; 2023 $72K for 850 services; 2024 $76K for 952 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 23 | 18 | $9.52 | $219 |
Medicare prescription drug claims, 2024
In 2024, the drug Benito A Marranzini prescribed most often to Medicare patients was Levothyroxine Sodium, with 2,361 prescriptions and refills. In total Benito A Marranzini wrote 15,066 Medicare prescriptions that cost $6.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 2,361 | 6,430 | 600 | $19K |
| Ozempic Semaglutide | 905 | 1,871 | 236 | $1.7M |
| Rosuvastatin Calcium Generic | 708 | 2,014 | 261 | $7,569 |
| Metformin Hcl Generic | 684 | 1,959 | 241 | $4,729 |
| Atorvastatin Calcium Generic | 624 | 1,748 | 225 | $5,044 |
| Jardiance Empagliflozin | 485 | 1,149 | 154 | $667K |
| Mounjaro Tirzepatide | 480 | 821 | 116 | $901K |
| Glipizide Generic | 370 | 1,047 | 134 | $3,458 |
| Januvia Sitagliptin Phosphate | 359 | 864 | 124 | $467K |
| Ezetimibe Generic | 342 | 938 | 128 | $5,676 |
| Alendronate Sodium Generic | 300 | 790 | 117 | $1,977 |
| Vitamin D2 Ergocalciferol (Vitamin D2) | 294 | 803 | 116 | $2,928 |
| Farxiga Dapagliflozin Propanediol | 277 | 607 | 84 | $329K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 273 | 728 | 101 | $47K |
| Synthroid Levothyroxine Sodium | 270 | 709 | 71 | $25K |
Brand drugs: 6,528 claims; generic drugs: 8,014 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Benito A Marranzini $5,536 ($5,536 in general payments such as food, travel and fees) from 33 companies. The largest payer was Novo Nordisk Inc with $487.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 18 | $487 |
| Corcept Therapeutics CORT | 23 | $473 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 27 | $415 |
| Dexcom, Inc. DXCM | 15 | $304 |
| Abbott Laboratories ABT | 16 | $294 |
| Insulet Corporation PODD | 18 | $293 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 17 | $286 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $282 |
| Amgen Inc. AMGN | 21 | $277 |
| Recordati_rare_diseases_inc. | 11 | $261 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.